eViralHepatitis Review: Recent Episodes
eViralHepatitis Review
Experts in viral hepatitis review topics in hepatitis C, hepatitis B, and coinfection using patient case scenarios. Certified for CME/CE credit.
Hosted on Acast. See acast.com/privacy for more information.
Take our post-test to claim CME credits.
To listen to our full-length podcast, click here.
Hosted on Acast. See acast.com/privacy for more information.
Take our post-test to claim CME credits.
To listen to our full-length podcast, click here.
Hosted on Acast. See acast.com/privacy for more information.
Take our post-test to claim CME credits.
To listen to our full-length podcast, click here.
Hosted on Acast. See acast.com/privacy for more information.
Hepatitis B. It may not be curable yet, but as our knowledge continues to grow, so does our ability to benefit our patients today as we prepare them for tomorrow. That’s the focus of this Special HBV Edition of eViralHepatitis Review.
The first part of this program presented an evidence-based expert commentary by eViralHepatitis Review Program Director Dr. Mark Sulkowski — Professor of Medicine at Johns Hopkins and Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. This second part is an interview providing more in-depth discussions between Dr. Sulkowski and three of medicine’s top CHB experts.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Why has finding a cure for hepatitis B infection been so challenging? What is it about this virus and its life cycle that makes it so different from curable HCV? In this issue, Dr. Marion Peters from the University of California San Francisco and Northwestern University explains the obstacles researchers face in their quest to tame this virus.
See acast.com/privacy for privacy and opt-out information.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hepatitis C has become “curable” for >90% of those infected. But while universal HCV elimination is medically possible, this goal is compromised by certain populations who remain underscreened, undertreated, and underserved and continue to spread the virus. One such population is people who inject drugs (PWID).
In this issue, Dr. Brianna Norton and Dr. Matthew Akiyama from the Albert Einstein College of Medicine analyze the most important data to explain how substance use impacts adherence and the risk of HCV reinfection.
See acast.com/privacy for privacy and opt-out information.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
The extrahepatic manifestations of chronic HCV can affect many different organ systems. In this eViralHepatitis Review podcast, Dr. Rajender Reddy from the University of Pennsylvania’s Perelman School of Medicine discusses clinical approaches to identifying and managing the effects of HCV infection beyond the liver.
See acast.com/privacy for privacy and opt-out information.
In this issue, Drs. Jordan Feld and Lisette Krassenburg from the Toronto Centre for Liver Disease at the University of Toronto apply the information in their recent newsletter issue to clinical practice.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
See acast.com/privacy for privacy and opt-out information.
In this podcast follow-up to their recent eViralHepatitis Review newsletter issue (Vol. 6, No. 5), Dr. Mandana Khalili and Dr. Michele Tana from the University of California, San Francisco discuss how their analysis of the newer published information can impact clinical practice.
Take our post-test to claim CME credits.
To read a companion newsletter click here
People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.
In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Among the many extrahepatic complications of hepatitis C infection that contribute to increased morbidity and mortality are CV (cryoglobulinemic vasculitis) and CKD chronic kidney disease).
In this issue, Dr. Paul Martin and Dr. Kalyan Ram Bhamidimarri from the Miller School of Medicine at the University of Miami discuss identification and management of these HCV-related comorbidities.
To read a companion newsletter click here.
Volume 5, Issue 12.
In this podcast Dr. Ira Jacobson discusses New Options for Patients with “Hard-To-Treat” Hepatitis C Infection.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post New Options for Patients with “Hard-To-Treat” Hepatitis C Infection appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 5, Issue 10.
In this podcast Dr. David Wyles discusses managing DAA failures with the newly approved treatment options for hepatitis C.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post Using Real World Data to Individualize HCV Management appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 5, Issue 8.
In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post Using Real World Data to Individualize HCV Management appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 5, Issue 6.
This podcast, Andrew H. Talal, MD, MPH and Richard Blondell, MD from the University at Buffalo discuss expanding HCV screening in persons with substance abuse disorders.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post Clinical Insights: HCV and Substance Use Disorder appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 5, Issue 4.
In this podcast Daryl T. Y. Lau, MD, MSc, MPH from Harvard Medical School discussed how to evaluate and mange patients who do not meet treatment criteria, the management of chronic hepatitis B during pregnancy, and how to identify patients appropriate for tenofovir alafenamide (TAF) therapy.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post Clinical Approaches to HBV Therapy appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 5, Issue 2.
Our guests authors are Mindie Nguyen, MD, MAS, from Associate Professor of Medicine at Stanford University, and Dr. Iris Liou, MD of the University of Washington.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post HBV: Addressing Current Gaps in Diagnosis and Linkage to Care appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 14.
Drs Jordan Feld, MD, MPH and Joel Emery, HBSc, MD cover the important topic of Extrahepatic Manifestations of Hepatitis C: Screening and Management in the format of case-study scenarios for the clinical practice.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post Extrahepatic Manifestations of Hepatitis C: Screening and Management appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 12.
Our guest author is Chloe Thio, MD, Professor of Medicine, Divison of Infectious Diseases at the Johns Hopkins University School of Medicine.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post Emerging Therapeutic Approaches for Chronic Hepatitis B appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 10.
Drs Kenneth Sherman, MD, PhD and Nadeem Anwar, MD cover the important topic of New Approaches to the Diagnosis and Management of Chronic HBV Infection in the format of case-study scenarios for the clinical practice.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post New Approaches to the Diagnosis and Management of Chronic HBV Infection appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 8, Part 3.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting.
The post Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 8, Part 2.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Michael Charlton from Intermountain Medical Center about his abstract: Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected with Chronic HCV Who Have Advanced Liver Disease or are Post Liver Transplant(SOLAR-1 & 2 Studies), presented at the April 2016 EASL meeting.
The post Resistance Analysis for Ledipasvir/Sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post Liver Transplant (SOLAR-1 and 2 STUDIES) appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 8, Part 1.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting.
The post High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 7.
Drs Paul Martin, MD and Kalyan Ram Bhamidimarri, MD cover the important topic of Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations in the format of case-study scenarios for the clinical practice.
The post Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 5.
Arthur Y. Kim, MD covers the important topic of Screening for HCV and HBV Infection in the Clinic in the format of case-study scenarios for the clinical practice.
The post Screening for HCV and HBV Infection in the Clinic appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 3, Part 3.
Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Gregory Dore from the Kirby Institute, UNSW Australia about the C-EDGE CO-STAR study.
The post Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 3, Part 2.
Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Graham Foster from Queen Mary University of London about the ASTRAL-3 study.
The post Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 3, Part 1.
Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Vincent Leroy from Grenoble University Hospital about the ALLY-3+ study.
The post Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 4, Issue 2.
David L. Wyles, MD covers the important topic of New DAAs and HCVV Genotype 2/3 Patients in the format of case-study scenarios for the clinical practice.
The post The New DAAs and HCV Genotype 2/3 Patients appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Special Edition 2014, Issue 2, Part 3.
Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.
The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Special Edition 2014, Issue 2, Part 2.
Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.
The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Special Edition 2014, Issue 2, Part 1.
Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.
The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Special Edition 2014, Issue 1, Part 2.
Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore discusses patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy with program director, Dr. Raymond Chung.
The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Special Edition 2014, Issue 1, Part 1.
Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore interviews Dr. David Nelson from the University of Florida about patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy.
The post INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 3, Issue 12.
Mark S. Sulkowski, MD, Professor of Medicine, Medical Director, Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology at the Johns Hopkins University School of Medicine, Raymond T. Chung, Associate Professor of Medicine, Harvard Medical School, Director of Hepatology, Vice Chief of Gastroenterology at Massachusetts General Hospital, and Laurent Castera, MD, PhD, Department of Hepatology, Beaujon Hospital, AP-AP, INSERM U773 at the University of Paris-Diderot. Discuss new information presented at the 2014 European Association for the Study of the Liver (EASL) meeting, as well as non-invasive markers of liver disease.
The post Highlights from the 2014 EASL Meeting appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 3, Issue 10.
David Thomas, MD, Professor of Medicine, and Director of the Division of Infectious Diseases at the Johns Hopkins University School of Medicine discusses HCV screening and natural history, in the form of case-study scenarios for the clinical practice.
The post HCV Screening and Natural History appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 3, Issue 8.
Susanna Naggie, MD, Professor, Assistant Professor of Medicine, Department of Medicine – Infectious Diseases at Duke University School of Medince discusses the development of new therapies for treating hepatitis C infection, and news about hepatitis B from the 64th meeting of the American Association for the Study of Liver Disease, as well as case-study scenarios for the clinical practice.
The post Susanna Naggie, MD Discussed HBV and HCV Coverage at AASLD appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 3, Issue 6.
Dr. Fabien Zoulim, MD, PhD, Professor, head of INSERM Viral Hepatitis Laboratory at the Medical School of Lyon, Lyon 1 University, Hepatology Department, Hospices Civils de Lyon in Lyon, France discusses the topic of HBV cure, in the form of case-study scenarios for the clinical practice.
The post Cure of Hepatitis B: Is it Achievable? appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 3, Issue 4.
Dr. Anna Suk-Fong Lok, MD, FRCP, Professor in the Department of Internal Medicine and Director of Clinical Hepatology in the Division of Gastroenterology at the University of Michigan Health System discusses predictive models for cirrhosis in the form of case-study scenarios for the clinical practice.
The post The Role of Prediction Models: Best practices in Identifying Cirrhosis and HCC in Patients Infected with HBV appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 3, Issue 2.
Dr. Mark Sulkowski from The Johns Hopkins University School of Medicine discusses advancements in hepatitis C therapy presented at EASL, as well as case-study scenarios for the clinical practice.
The post European Association for the Study of the Liver HCV Update appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 2, Issue 12.
Dr. Raymond Chung presents three patient cases on the topic of hepatitis C and host genetics.
The post Hepatitis C and Host Genetics appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 2, Issue 10.
Dr. David Wong presents three patient cases on the topic of HBV Reactivation.
The post Reactivation of Hepatitis B Virus Infection appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 2, Issue 8.
Dr. Mark Sulkowski, Professor and Medical Director of the Viral Hepatitis Center at Johns Hopkins University School of Medicine will describe the epidemiology of HCV infection in HIV-infected persons including the role of sexual transmission of HCV.
The post HCV/HIV Coinfection appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 2, Issue 6.
Dr. Kennenth Sherman, Gould Professor of Medicine and Director of the Division of Digestive Disease at the University of Cincinnati College of Medicine will diferentiate how occult HBV differs from classical HBV infections.
The post Occult Hepatitis B Virus Infection appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.
Volume 2, Issue 4-Hepatitis B and Pregnancy.
Dr. Tram T Tran, Medical Director of the Liver Transplantation Program at the Liver Disease and Transplant Center at Cedars-Sinai Medical Center and Associate Professor of Medicine at the David Geffen School of Medicine at UCLA will present patient case scenarios which: review current screening recommendations for hepatitis B, Assess strategies to reduce mother-to-child transmission (MTCT) of hepatitis B, and review recommendations and vaccination of hepatitis B infected mothers.
The post Dr. Tram T. Tran will cover issues related to Hepatitis B and Pregnancy appeared first on DKBmed Radio.
See acast.com/privacy for privacy and opt-out information.